Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Art of Waiting: Making COVID-19 Vaccine Rollouts More Efficient and Cutting Wait Times

The approval of several vaccines against the novel coronavirus is welcome news around the world. Now that there are vaccines proven to work, the struggle has become how to get those shots from labs to human bodies. It’s tough to consume news coverage and not see scenes of long lines of cars or people…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
The Art of Waiting: Making COVID-19 Vaccine Rollouts More Efficient and Cutting Wait Times

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The approval of several vaccines against the novel coronavirus is welcome news around the world. Now that there are vaccines proven to work, the struggle has become how to get those shots from labs to human bodies.

It’s tough to consume news coverage and not see scenes of long lines of cars or people at vaccine rollout sites as counties and states wrestle with the best way to begin protecting people in their communities.

Those lines may be preventable, said Erik Berg, VP of Marketing for NEMO-Q, and it starts with understanding exactly how many people a facility can handle and when they should be asked to join the queue.

“Where we come in is we provide lots of crucial KPIs so these facilities can be as efficient as possible,” Berg said. “Second, when it comes to vaccinating people and getting people tested, 60 seconds adds up to a minute, 60 minutes add up to an hour and so on. We really provide incredibly detailed service times, what you can expect and how long it will take to vaccinate people or test them, so we can get people in and out as quickly and efficiently as possible.”

Providers or government agencies may think their hands are tied by the price of a system like NEMO-Q’s, but the company is working to help stop the spread of COVID-19, as well, and has an affordable and easy-to-use solution for most vaccine providers.

“It is incredibly cost-effective and simple on the end of the healthcare provider,” Berg said. “They’re pretty much hands-off with the process. We know what they need at this point, so we’re looking to be as big of an ally as possible. The budget can stay low. Even some of our more cost-effective, simpler products can make a world of difference when it comes to getting these patients seen as quickly as possible,” Berg said. “We’re willing to work with all these healthcare facilities as best we can.”

With the company’s experience working with healthcare providers even before the pandemic started, solutions required now during the peak of the pandemic can be easily repurposed when the situation improves and things like flu shots, routine appointments, or aches and pains become the primary focus once again. With effective queuing solutions, that could happen even faster than expected.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

ADA endorsement puts Weave on the shortlist for dental front-office tech

ADA endorsement puts Weave on the shortlist for dental front-office tech

Weave was named the exclusive patient engagement platform endorsed for American Dental Association members in March 2026. It lands as practices add more front-office systems. Weave’s Practice Analytics, launched in 2023, adds real-time metrics tied to Dentrix, Open Dental, and Eaglesoft.

  • 01Endorsements are becoming a procurement accelerant in dental tech: the ADA Member Advantage designation can move Weave into “default vendor” conversations when practices refresh phone, texting, reminders, and payments.
  • 02Analytics is moving from retrospective reporting to daily work queues: Weave’s Practice Analytics is positioned around unscheduled treatment plans, cancellations, and time-between-treatments, metrics that can be assigned to staff, not just reviewed by owners (according to Dental Products Report).
  • 03This matters most for groups standardizing across multiple sites: Business Wire frames Weave Enterprise as built to centralize operations across dozens or hundreds of locations, turning “patient communication” into a rollout and governance problem, not a single-office tool choice.

Sep 3, 2026

Radiology deal flow is splitting in two: $8B radiopharma and 14-state mobile imaging rollups

Radiology deal flow is splitting in two: $8B radiopharma and 14-state mobile imaging rollups

Radiology consolidation in 2026 is widening into two operationally different tracks: very large upstream radiopharma and imaging-component deals, and regional service platforms that bring imaging capacity to hospitals via mobile units and leased equipment. Radiology Business reported Curium signed a definitive agreement to acquire Lantheus for up to $8B after earlier reports put a potential deal near $7B, while Align Capital Partners agreed to buy Boise-based Heritage Imaging, a mobile diagnostic provider serving facilities across 14 states. For health systems, the immediate impact shows up less in headlines than in procurement and staffing: vendor portfolios can change quickly after component M&A, while outsourced and mobile imaging platforms change how rural and community facilities source PET-CT, MRI, and nuclear medicine capacity. Radiology Today’s management guidance on radiology mergers points to integration discipline, physician alignment, and process as the determinants of whether consolidation translates into measurable access and throughput improvements on the ground.

  • 01The same word, “consolidation,” now covers two very different buying problems: upstream supply and R&D bets (radiopharma, components) versus front-line capacity (mobile imaging and outsourced service lines).
  • 02Heritage Imaging’s 14-state footprint is a concrete benchmark for how far a mobile imaging platform can spread before standardization of protocols, credentialing, and PACS/RIS interfaces becomes the real work.
  • 03When deal values move from “reported” to “definitive” (as with Curium and Lantheus), procurement teams should assume faster portfolio and contracting changes, and pull forward vendor roadmap reviews tied to nuclear medicine and theranostics growth plans.

Sep 3, 2026

Direct-to-consumer telehealth raises spending, even as ASC investment surges

Direct-to-consumer telehealth raises spending, even as ASC investment surges

A Health Affairs analysis of commercial claims data (2011–13) found 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization, with net annual spending on acute respiratory illness increasing $45 per telehealth user. Separately, MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

  • 01The most actionable benchmark for finance teams evaluating DTC telehealth is substitution rate, not visit growth. Health Affairs measured 12% substitution and 88% new utilization in commercial claims for acute respiratory illness.
  • 02The $45 per-user net annual spend increase in the Health Affairs analysis is small enough to hide in PMPM reporting but large enough to matter at scale, and it should be stress-tested against virtual-visit eligibility rules and repeat-use patterns.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512